期刊文献+

瑞舒地尔关键中间体的合成工艺改进和优化 被引量:1

Synthesis and condition optimization of key intermediate for ripasudil
下载PDF
导出
摘要 以L-2-氨基-1-丙醇为原料,用邻硝基苯磺酰氯(NsCl)保护其氨基后,再与3-氨基-1-丙醇进行取代反应,仲氨用叔丁氧甲酰基(Boc)保护后,经分子内Mitsunobu环合反应,用十二硫醇脱去邻硝基苯磺酰保护基,生成瑞舒地尔关键中间体(S)-3-甲基-1-叔丁氧甲酰基-1,4-二氮杂环庚烷(Ⅰ)。改进后的工艺路线更为简短,易于操作,总收率提高到46.4%,手性异构体杂质HPLC含量<0.1%,已用于中试放大生产。 Key intermediate(S)-3-methyl-1-tert-butylcarbonyl-1, 4-diaza cyclic heptane(Ⅰ) for ripasudil was synthesized from intramolecular Mitsunobu cyclization reaction of intermediates, which was treated with tert-butoxyformyl(Boc) for secondary amine group protection and obtained from substitution reaction of 3-amino-1-propanol with L-2-amino-1-propanol, which was treated with o-nitrobenzenesulfonyl chloride for amino group protection and o-nitrobenzenesulfonyl group protection was later removed by dodecanthiol in the last step. The improved process, with reducing manufacturing time and easier operation, led to total yield increased up to 46.4% and chiral isomer impurity HPLC content less than 0.1%. This improved process had been upscaled for pilot production.
作者 陈铖 邱康 丁浩 吴伟锋 王方道 陆群 CHEN Cheng;QIU Kang;DING Hao;WU Weifeng;WANG Fangdao;LU Qun(School of Life Science and Engineering,Southwest Jiaotong University,Chengdu 610031,Sichuan,China;Chemvon Biotechnology(Shanghai)Co.,Ltd.,Shanghai 201202,China)
出处 《精细化工》 EI CAS CSCD 北大核心 2022年第10期2155-2160,共6页 Fine Chemicals
基金 四川省科技支撑计划项目(2015FZ0016)。
关键词 瑞舒地尔 手性高哌嗪 L-2-氨基丙醇 工艺改进 精细化工中间体 ripasudil chiral homopiperazine L-2-aminopropanol process improvement fine chemical intermediates
  • 相关文献

参考文献2

二级参考文献8

  • 1五味宣明,扇谷忠明,涩谷公幸.异喹啉衍生物或其盐的新制造方法:中国,103068818A[P].2013-04-24.
  • 2大岛武,日高弘义,白土正三,等.(S)-(-)-1-(4-氟异喹啉-5-基)磺酰基-2-甲基-1,4-高哌嗪盐酸盐-二水合物:中国,101068806A[P].2007.11-07.
  • 3Garnock-Jones KP. Ripasudil: First global approval [J]. Drugs, 2014, 74(18): 2211--2215.
  • 4Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure- lowering effects ofa Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study [J]. Acta Ophthalmologica, 2015, 93 (4) : 254--260.
  • 5Gomi N, Ohgiya T, Shibuya K, et al. A practical synthesis of novel Rho-kinase inhibitor, (S)-4-fluoro-5-(2-methyl-l,4- diazepan-l-ylsulfonyl) isoquinoline [J]. Heterocycles, 2011, 83 (8) : 1771--1781.
  • 6Sumi K, Inoue Y, Nishio M, et al. IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys [J].Bioorg Med Chem Lett, 2014, 24 (3) : 831--834.
  • 7Gomi N, Higashimurayama S, Ohgiya T, et al. Novel production method for isoquinoline derivatives and salts thereof: US, 2013 0144054 [P]. 2013-06-06.
  • 8Phani Krishna Kondamudi,Rajkumar Malayandi,Chandramohan Eaga,Deepika Aggarwal.Drugs as causative agents and therapeutic agents in inflammatory bowel disease[J].Acta Pharmaceutica Sinica B,2013,3(5):289-296. 被引量:2

共引文献8

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部